Archive · 20 Jul 2026
Big Pharma Bets Billions on Psychedelic Medicine
Big Pharma companies like Eli Lilly are investing billions in psychedelic drugs, which have been used recreationally for decades.
They are studying these drugs to see if they can help people with depression, PTSD, and anxiety.
These drugs work differently from regular antidepressants and might help reset the brain.
Eli Lilly recently bought a company called AtaiBeckley for $3.8 billion to develop a nasal spray called BPL-003.
This spray is being tested for people who don't get better with regular treatments.
The drugs can have side effects, but if they work, they could be a big help for mental health.
In India, these drugs are not yet approved for regular use, but if they succeed elsewhere, India might change its rules.
Eli Lilly acquires AtaiBeckley for $3.8 billion to develop psychedelic treatments for mental health.
BPL-003, a nasal spray derived from 5-MeO-DMT, is being tested for treatment-resistant depression.
Psychedelics like psilocybin, LSD, and MDMA are being studied for their potential to boost neuroplasticity and offer faster-acting alternatives to conventional antidepressants.
The market for psychedelic treatments is growing, with Spravato (esketamine) already showing commercial success.
India currently does not approve psychedelic therapies for routine mental-health treatment, but this could change with further research and regulatory approvals abroad.
- Who
- Eli Lilly and AtaiBeckley
- What
- Acquisition of AtaiBeckley by Eli Lilly for psychedelic drug development
- When
- Recent deal, with Phase 3 trials expected to conclude by 2029
- Where
- Global, with potential implications for India's mental healthcare
- Why
- To explore the potential of psychedelics in treating mental health conditions like depression, PTSD, and anxiety
Proponents of Psychedelic Medicine
Skeptics of Psychedelic Medicine
Efficacy and Potential
Proponents of Psychedelic Medicine
Proponents argue that psychedelics like psilocybin, LSD, and MDMA show promise in treating depression, PTSD, and anxiety by boosting neuroplasticity and offering faster-acting alternatives to conventional antidepressants.
Skeptics of Psychedelic Medicine
Skeptics highlight the experimental nature of these treatments and the lack of long-term data on their efficacy and safety, noting that the drugs can cause intense perceptual changes and other risks.
Market Potential
Proponents of Psychedelic Medicine
Supporters point to the success of drugs like Spravato (esketamine) as evidence that there is a market for psychedelic-based treatments, potentially generating billions in sales.
Skeptics of Psychedelic Medicine
Critics argue that the high costs and regulatory hurdles, along with the need for medical supervision, could limit the widespread adoption and commercial viability of these treatments.
- Company
- Eli Lilly
- Acquisition Target
- AtaiBeckley
- Deal Value
- $3.8 billion
- Experimental Drug
- BPL-003 (5-MeO-DMT nasal spray)
- Target Condition
- Treatment-resistant depression
- Potential Market
- $1–2 billion annually
- Regulatory Status in India
- Not approved for routine mental-health treatment